AML: Expert Guidance on Current Standards and New Directions in Patient Care
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for physicians, nurses, pharmacists, physician assistants, and other healthcare providers who treat and manage patients with AML.
Upon completion of this activity, participants should be able to:
- Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions.
- Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations.
- Plan evidence-based therapeutic strategies using novel targeted agents or formulations and refinements of conventional chemotherapy.
- Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody-based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell-based therapy.
- Manage treatment-related toxicities associated with novel therapeutics.
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center
Amir T. Fathi, MD
Massachusetts General Hospital
Jeffrey E. Lancet, MD
Moffitt Cancer Center
Farhad Ravandi, MD
The University of Texas MD Anderson Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Amir Fathi, MD, has disclosed that he has received research support from Agios, Celgene, and Takeda; has received consulting fees from Agios, Astellas, Celgene, Daiichi Sankyo, and Forty Seven; and has served on advisory boards for Amphivena, Jazz, NewLink Genetics, Pfizer, and PTC Therapeutics.
Jeffrey E. Lancet, MD, has disclosed that he has received consulting fees from AbbVie, Agios, Daiichi Sankyo, Jazz, and Pfizer.
Farhad Ravandi, MD, has disclosed that he has received research support from AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Jazz, Macrogenix, Orsenix, and Xencor; consulting fees from AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Orsenix, and Xencor; and honoraria from AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Novartis, Orsenix, and Xencor.
Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Agios, Amgen, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, Pfizer, and Stemline and honoraria from Pfizer and Stemline.
The activity planning staff listed below disclose no relevant financial relationships:
CCO: Terrence Fagan; Timothy A. Quill, PhD; Gordon Kelley; Kevin Obholz, PhD; Jason J. Everly, PharmD, BCOP, CHCP; June Wasserstrom; and Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
CCO activity planning staff member Jim Mortimer has disclosed that his spouse has received salary/ownership interest from AstraZeneca.
NCCN clinical staff member Ndiya Ogba, PhD, discloses that she has no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 3.0 contact hours.
NCCN designates this application-based continuing education activity for 3.0 contact hours (0.3 CEUs) of continuing education credit. UAN: JA4008196-9999-19-070-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 3.00 AAPA Category 1 CME credit
- 3.00 ACPE contact hours
- 3.00 AMA PRA Category 1 Credit™
- 3.00 ANCC contact hours
- 3.00 Participation